Chile - español - ISPC (Instituto de Salud Pública de Chile)

knop laboratorios s.a. - arsenic. jodat. c6 0,166 ml; cuprum aceticum c6 0,166 ml; drosera c6 0,166 ml; lycopodium c6 0,166 ml; spongia c6 0,166 ml; sticta pulmonaria c6 0,166 ml - antitusigeno homeopatico

Chile - español - ISPC (Instituto de Salud Pública de Chile)

productos farmacÉuticos heel chile ltda. - altropa belladonna d4 20,0 g; arsenum iodatum d6 20,6 g; causticum hahnemanni d6 30,0 g; cuprum accticum d6 10,0 g; urginea maritima var. rubra d4 20,0 g - medicamento homeopatico antitusivo

Chile - español - ISPC (Instituto de Salud Pública de Chile)

productos farmacÉuticos heel chile ltda. - aconitum napellus d6 60 mg; amanita muscaria d4 15 mg; ammonium bromatum d4 30 mg; atropina sulfuricum d6 30 mg; chamomilla recutita d3 15 mg; citrullus colocynthis d4 30 mg; cuprum sulfuricum d6 15 mg; gelsemium sempervirens d6 30 mg; magnesium phosphoricum d6 30 mg; passiflora incarnata d2 15 mg; veratrum album d6 30 mg - medicamento homeopatico antiespasmodico

Chile - español - ISPC (Instituto de Salud Pública de Chile)

productos farmacÉuticos heel chile ltda. - aconitum napellus d6 2,2 mg ampollas; agaricus d4 0,55 mg ampollas; ammonium bromatum d4 1,10 mg ampollas; atropinum sulfuricum d6 1,10 mg ampollas; citrullus colocynthys d4 1,10 mg ampollas; cuprum sulfuricum d6 0,55 mg ampollas; gelsemium sempervirens d6 1,10 mg ampollas; magnesium phosphoricum d6 1,10 mg ampollas; matricaria recutita d3 0,55 mg ampollas; passiflora incarnata d2 0,55 mg ampollas; veratrum album. d6 1,10 mg ampollas - coadyuvante en alivio de cuadros espasmódicos del tracto digestivo.

Venezuela - español - Instituto Nacional de Higiene

representaciones nolver c.a. - granisetron - comprimido recubierto - 1 mg (a)

Venezuela - español - Instituto Nacional de Higiene

representaciones nolver c.a. - granisetron - solucion inyectable - 3 mg/3 ml (a)

Unión Europea - español - EMA (European Medicines Agency)

bayer ag - riociguat - hipertensión, pulmonar - antihipertensivos para la hipertensión arterial pulmonar - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. la eficacia se ha demostrado en un pah la población, incluyendo a las etiologías de la idiopático o hereditario hap o pah asociada con enfermedad del tejido conectivo. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.

Unión Europea - español - EMA (European Medicines Agency)

merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimicóticos para uso sistémico - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.

Unión Europea - español - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - pneumococcal polysaccharide conjugate vaccine (adsorbed) - infecciones neumocócicas - pneumococcus, purified polysaccharides antigen conjugated - vaxneuvance is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. ver secciones 4. 4 y 5. 1 para obtener información sobre la protección contra serotipos neumocócicos específicos. the use of vaxneuvance should be in accordance with official recommendations.

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

strides pharma (cyprus) limited - acidos omega 3 esteres etilicos - cÁpsula blanda - 1.000 mg - acidos omega 3 esteres etilicos 1000 mg - triglicéridos omega-3, incluidos otros ésteres y ácidos